Search

Displaying results 6271 - 6280 of 9881 in total
  1. Drug

    Selumetinib

    go.drugbank.com/drugs/DB11689
    ApprovedInvestigational

    [A193608] It is a genetic, autosomal dominant condition resulting from mutations of the NF1 gene, which can lead to various complications, including the development of multiple tumours in the nervous system

  2. Drug

    Tropisetron

    go.drugbank.com/drugs/DB11699
    ApprovedInvestigationalWithdrawn

    As a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting

  3. Drug

    Linerixibat

    go.drugbank.com/drugs/DB11729
    ApprovedInvestigational

    Linerixibat is a first-in-class and small-molecule inhibitor of the ileal bile acid transporter (IBAT). … [L56127] PBC is a rare, chronic autoimmune liver disease characterized by the destruction of small bile ducts, leading to cholestasis and the systemic accumulation of bile acids, which are hypothesized

  4. Drug

    Esketamine

    go.drugbank.com/drugs/DB11823
    ApprovedInvestigational

    Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide. … Ketamine is a mixture of two enantiomers (mirror image molecules). This is the first time that the FDA has approved esketamine for any use. The FDA approved ketamine (Ketalar) in 1970.

    Synonyms: L-ketamineCategories: Non-Competitive N-Methyl D-Aspartate (NMDA) Receptor Antagonists
  5. Drug

    Mocetinostat

    go.drugbank.com/drugs/DB11830
    Investigational

    Mocetinostat has been used in trials studying the treatment of Lymphoma, Urothelial Carcinoma, Relapsed and Refractory, Myelodysplastic Syndrome, and Metastatic Leiomyosarcoma, among others.

  6. Drug

    Varespladib

    go.drugbank.com/drugs/DB11909
    Investigational

    Varespladib has been investigated for the treatment and prevention of Sickle Cell Disease, Vaso-occlusive Crisis, and Acute Coronary Syndrome.

    Categories: Phospholipases A, antagonists & inhibitors
  7. Drug

    Valbenazine

    go.drugbank.com/drugs/DB11915
    ApprovedInvestigational

    [A261165] However, challenges in using [tetrabenazine] as a treatment of tardive dyskinesia included frequent dosing and safety and tolerability concerns. … [L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine receptor therapy, and until 2008 with the advent of [tetrabenazine], most treatments were ineffective.

  8. Drug

    Difelikefalin

    go.drugbank.com/drugs/DB11938
    ApprovedInvestigational

    [A237610] These revelations led to the study of KOR agonists as a potential treatment option in patients suffering from pruritic conditions. … [A237615,A237620] The clinical burden of uremic pruritus in this patient population is being increasingly recognized as contributing to a significant reduction in patient quality of life, poor outcomes

  9. Drug

    Benralizumab

    go.drugbank.com/drugs/DB12023
    ApprovedInvestigational

    Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils

  10. Drug

    Gadolinium

    go.drugbank.com/drugs/DB12091
    ApprovedInvestigationalWithdrawn

    Gadolinium is under investigation in Hypertension, ACUTE KIDNEY INJURY, and Chronic Kidney Disease. Gadolinium has been investigated for the basic science of CAD, Multiple Sclerosis, and Coronary Artery Disease.

    Categories: Compounds used in a research, industrial, or household setting